As of May 2021, U.S. investor Blackrock Inc owned more than ***** percent of total shares of pharmaceutical companies AstraZeneca, Pfizer, Novavax, and Johnson & Johnson, respectively. The statistic illustrates major shareholdings at select pharmaceutical companies which are involved in the development and production of COVID-19 vaccines as of May 2021, by investor.

Content

Stock data of the following companies from Oct 2019 is included in this dataset. (BioNTech , Moderna , Johnson & Johnson , Inovio Pharmaceuticals, Sinovac , Sinopharm , Novavax ,Astrazeneca(Oxford)) (The date 2019 was chosen because few companies got IPO just in 2019)

Inspiration

To do more analysis on the performance of the companies with the influence of covid vaccine.

End note

Please let me know if any more companies are to be included or any changes have to be made to improve the quality of the dataset in the discussion section.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in vacc

The global market for Novel Coronavirus Inactivated Vaccines experienced significant growth driven by the COVID-19 pandemic. While precise market size data for 2019-2024 isn't provided, we can infer substantial expansion based on the widespread vaccine rollout. Let's assume a conservative 2024 market size of $15 billion, considering the immense global vaccination campaigns. Assuming a Compound Annual Growth Rate (CAGR) of 10% (a figure reflecting both continued demand for booster shots and potential new variants requiring updated vaccines), the market is projected to reach approximately $25 billion by 2025 and continue to grow steadily. This growth is fueled by ongoing vaccination efforts, particularly in developing nations with lower vaccination rates, and the potential for future pandemics. Factors such as government initiatives supporting vaccine development and distribution, along with the evolving understanding of COVID-19 and its long-term effects, are key drivers. However, market growth will likely moderate in the coming years as initial pandemic-related urgency subsides. Factors like waning immunity, the emergence of new variants, and the potential for alternative prophylactic measures will influence the long-term trajectory. The market is segmented by type (adult and child formulations) and application (hospitals and clinics). Leading companies involved in the production and distribution of these vaccines include Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer, Johnson & Johnson, and several prominent Chinese pharmaceutical companies. The Asia-Pacific region, particularly China and India, is expected to exhibit significant growth, driven by their large populations and increasing healthcare infrastructure. The forecast period of 2025-2033 presents opportunities and challenges. While the initial surge in demand is likely to slow, consistent demand for booster shots and potential new vaccine formulations adapted to emerging variants will sustain market growth. The continued development of more effective and convenient vaccine delivery methods, coupled with global health initiatives aiming to improve vaccination access in underserved communities, will be critical factors influencing the market trajectory. Competition among pharmaceutical companies will remain intense, necessitating innovation and strategic partnerships. Regulatory approvals and safety concerns will also play pivotal roles in shaping market dynamics throughout the forecast period. By 2033, a more mature market is anticipated, with a focus on innovation, long-term preventative strategies, and sustainable growth.

The coronavirus pandemic has affected the entire world and many families have been destroyed. The stock exchange was also affected, but vaccine companies took advantage of this moment and leveraged their profits

Biotech companies:

• PFIZER: Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas.

• ASTRAZENECA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• BIONTECH: BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

• MODERNA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• NOVAVAX: Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases.

Check the movement of the financial market through this dataset

Use your creativity and external information

The global vaccine market, including COVID-19 vaccines, is a dynamic and rapidly evolving sector. With a 2025 market size of $58,060 million and a projected Compound Annual Growth Rate (CAGR) of 3.7% from 2025 to 2033, significant growth is anticipated. This expansion is driven by several factors, including rising prevalence of vaccine-preventable diseases, increasing government initiatives promoting vaccination programs, and advancements in vaccine technology leading to the development of more effective and safer vaccines. The COVID-19 pandemic significantly accelerated vaccine development and deployment, boosting market growth and highlighting the crucial role of vaccines in public health. However, challenges remain, including vaccine hesitancy, the high cost of vaccine development and distribution, and the need for continuous research and development to combat emerging infectious diseases and adapt to evolving viral strains. The market is highly competitive, with major players like Pfizer, Sanofi, AstraZeneca, and several prominent Chinese and Indian manufacturers vying for market share. Future growth will likely be influenced by the success of new vaccine candidates, the effectiveness of ongoing vaccination campaigns, and the emergence of new pandemic threats. The market is segmented based on vaccine type (live attenuated, inactivated, etc.), disease indication (influenza, measles, COVID-19, etc.), and route of administration. Geographical variations in vaccination rates and healthcare infrastructure will also influence regional market performance. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotechnology companies. Strategic partnerships, mergers and acquisitions, and continuous innovation are shaping the market dynamics. The increasing focus on personalized medicine and the development of next-generation vaccines, such as mRNA vaccines and gene-based vaccines, offer significant growth opportunities. However, regulatory hurdles and the stringent safety requirements associated with vaccine development pose significant challenges. To further fuel growth, companies are investing heavily in R&D to develop novel vaccines with improved efficacy, safety profiles, and ease of administration. This includes advancements in delivery systems like needle-free options and the exploration of combination vaccines to reduce the number of injections needed. Furthermore, global collaborations and investments in vaccine manufacturing capacity are crucial to ensure equitable access to vaccines worldwide.

Covid-19 Vaccine Logistics Market Outlook

The global Covid-19 Vaccine Logistics market size was valued at approximately USD 12.5 billion in 2023 and is projected to reach USD 18.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period. The growth of the market is primarily driven by the urgent global need for effective and efficient distribution of Covid-19 vaccines, along with the continuous advancements in logistics technology and infrastructure.

One of the primary growth factors driving the Covid-19 Vaccine Logistics market is the unprecedented global demand for Covid-19 vaccines. The pandemic has highlighted the critical need for rapid and reliable vaccine distribution to curb the spread of the virus and achieve herd immunity. Governments and healthcare organizations are investing heavily in logistics to ensure that vaccines are delivered safely and efficiently to all corners of the world. Additionally, the development of multiple vaccine types, each with specific storage and handling requirements, has further fueled the need for specialized logistics services.

Another significant factor contributing to the market's growth is the technological advancements in the logistics sector. Innovations such as temperature-controlled packaging, real-time tracking systems, and advanced cold chain solutions have revolutionized the way vaccines are transported and stored. These technologies ensure that vaccines remain effective throughout the distribution process, reducing the risk of spoilage and wastage. The integration of Internet of Things (IoT) devices and blockchain technology in vaccine logistics has also improved transparency and traceability, enhancing the overall efficiency and reliability of the supply chain.

The increasing collaboration between public and private sectors is also a key driver of market growth. Governments, pharmaceutical companies, and logistics providers are working together to develop robust distribution networks and overcome logistical challenges. Public-private partnerships (PPPs) have facilitated the sharing of resources, expertise, and infrastructure, leading to more effective vaccine distribution strategies. Additionally, financial support from international organizations and initiatives such as COVAX has played a crucial role in ensuring equitable access to vaccines, particularly in low- and middle-income countries.

From a regional perspective, North America and Europe have been at the forefront of Covid-19 vaccine logistics due to their advanced healthcare infrastructure and strong logistics capabilities. However, significant growth opportunities exist in the Asia Pacific and Latin America regions, driven by the large population base and increasing government initiatives to improve healthcare access. The Middle East & Africa region also presents potential growth opportunities, albeit at a slower pace, due to ongoing efforts to enhance their logistics networks and healthcare infrastructure.

Service Type Analysis

In the Covid-19 Vaccine Logistics market, the service types are categorized into transportation, warehousing, packaging, and others. Each of these services plays a crucial role in ensuring the timely and safe delivery of vaccines.

Transportation services are the backbone of vaccine logistics, involving the movement of vaccines from manufacturing facilities to distribution centers and, ultimately, to vaccination sites. This segment is critical due to the need for specialized vehicles equipped with temperature-controlled systems to maintain the integrity of vaccines. Air transport has been particularly significant for long-distance and international shipments, offering speed and reliability. Road transport, on the other hand, is essential for last-mile delivery, ensuring vaccines reach even the most remote areas.

Warehousing services are another vital component of vaccine logistics. Proper storage facilities are necessary to maintain the required temperature conditions for vaccines. Cold storage warehouses equipped with advanced refrigeration systems ensure that vaccines remain effective until they are dispatched for distribution. The demand for warehousing services has surged, leading to investments in expanding existing facilities and constructing new ones to handle the increased volume of vaccines.

Packaging services in vaccine logistics involve the use of specialized materials and techniques to protect vaccines during transit. Temperature-sensitive packaging solutions, such as insulated contai

The 2019 coronavirus (COVID-19) pandemic revealed the urgent need for the acceleration of vaccine development worldwide. Rapid vaccine development poses numerous risks for each category of vaccine technology. By using the Risklick artificial intelligence (AI), we estimated the risks associated with all types of COVID-19 vaccine during the early phase of vaccine development. We then performed a postmortem analysis of the probability and the impact matrix calculations by comparing the 2020 prognosis to the contemporary situation. We used the Risklick AI to evaluate the risks and their incidence associated with vaccine development in the early stage of the COVID-19 pandemic. Our analysis revealed the diversity of risks among vaccine technologies currently used by pharmaceutical companies providing vaccines. This analysis highlighted the current and future potential pitfalls connected to vaccine production during the COVID-19 pandemic. Hence, the Risklick AI appears as an essential tool in vaccine development for the treatment of COVID-19 in order to formally anticipate the risks, and increases the overall performance from the production to the distribution of the vaccines. The Risklick AI could, therefore, be extended to other fields of research and development and represent a novel opportunity in the calculation of production-associated risks.

The biopharmaceutical vaccine market, encompassing the production and distribution of vaccines derived from biological sources, is experiencing robust growth. While precise market sizing data is unavailable, considering the presence of major players like Pfizer, Novartis, and Sanofi, and the ongoing demand driven by infectious disease outbreaks and increasing preventative healthcare initiatives, a reasonable estimate for the 2025 market size would be in the range of $100 billion USD. This sector benefits from a high CAGR (let's assume, for illustrative purposes, a CAGR of 8% based on industry averages for similar rapidly advancing sectors), projected to continue its upward trajectory through 2033. Key drivers include the continuous emergence of novel pathogens necessitating new vaccine development, increasing government funding for vaccine research and development, and rising public awareness regarding the importance of vaccination. Furthermore, technological advancements in mRNA and vector-based vaccine platforms are accelerating innovation, leading to more effective and easily deployable vaccines. However, market growth is not without its challenges. Regulatory hurdles, high research and development costs, and the complex logistical requirements of vaccine distribution, especially in underserved regions, act as significant restraints. Market segmentation is primarily driven by vaccine type (e.g., mRNA, viral vector, subunit), target disease (e.g., influenza, COVID-19, HPV), and geographic region. The leading companies mentioned—Novartis, Pfizer, Sanofi, Roche, Abbott, Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Johnson & Johnson, GlaxoSmithKline, Merck, Lonza, and FUJIFILM Diosynth Biotechnologies—are actively engaged in research, manufacturing, and distribution, contributing to market competitiveness. Future market performance hinges on sustained R&D investment, effective regulatory frameworks, and equitable vaccine access worldwide. A proactive approach to addressing these factors will ensure the continued growth and positive societal impact of the biopharmaceutical vaccine industry.

COVID-19 Reopening Data from Associated Press and Kantar Media

Access regularly updated data from The Associated Press and Kantar Media containing information on events at the global, national and state levels as economies reopen following the coronavirus pandemic via AP Planner.

AP Planner is a paid service from The Associated Press & Kantar Media.

The four data files below feature the following event types:

• Environmental, Social and Governance (ESG): Events related the factors that measure the sustainability and societal impact of an investment in a company or business.
• Healthcare, Pharmaceuticals and Bio Tech: Health care providers and services, health care equipment and supplies, and health care technology companies. Drug and vaccine production, as well as biological substances for the purposes of drug discovery and diagnostic development.
• Politics: U.S. political news and events.
• Diversity and Discrimination: News and events related to race, religion, gender, sexuality, disability and age.

All data is compiled by a dedicated staff with over 15 years of forward planning research experience, employing data verification and processes designed to provide reliable and up-to-date information.

The data can be used to help:

• Provide signals to investors on how to act and at what speed based on the types of events returning across industries.
• Analyze risk associated with companies based on when they're reopening.
• Retain your own customer base based on reopening dates for vendors and competitors.
• Track COVID regulations to prepare inventory and guest policies.

The following data files are samples - if you are interested in licensing the full, regularly updated database, please contact Opal Barclay (obarclay@ap.org) at The Associated Press or Click on Request Access Button above.

​

***

FAQs

Why does AP and Kantar compile this data?_ The data is sourced from AP Planner, a product offered by The Associated Press and Kantar Media. AP Planner is a searchable database of future events that is updated daily and intended for research, not publication.

What information does AP Planner contain?_ AP Planner is global in scope and contains more than 100,000 U.S. and international events from the world of news, current affairs, politics, business, lifestyle and more - all searchable up to 12 months ahead.

Where does the information come from?_ AP Planner aggregates listings from tens of thousands of organizations worldwide. Our research staff monitors over 350,000 websites and uses a verity of secondary sources including press releases, corporate announcements and other outlets to ensure accuracy.

How can I be confident of the data's quality and accuracy?_ We have a dedicated research staff with over 15 years of forward planning research experience. They employ data verification and updating processes designed to provide our customers with completely reliable and up-to-date information.

Can I export data into other applications?_ Yes, AP Planner data can be exported as an Excel file or an Outlook calendar file. The data is also accessible via API.

Who can I contact to learn more about AP Planner?_ Opal Barclay, obarclay@ap.org.

SB: AK: COVID Test/Vaccine: Proof of COVID Vaccination: No data was reported at 83.400 % in 11 Apr 2022. This records an increase from the previous number of 79.700 % for 04 Apr 2022. SB: AK: COVID Test/Vaccine: Proof of COVID Vaccination: No data is updated weekly, averaging 65.600 % from Feb 2021 (Median) to 11 Apr 2022, with 45 observations. The data reached an all-time high of 90.200 % in 05 Jul 2021 and a record low of 65.600 % in 13 Sep 2021. SB: AK: COVID Test/Vaccine: Proof of COVID Vaccination: No data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S: Small Business Pulse Survey: by State: West Region: Weekly, Beg Monday (Discontinued).

Context

The research shows that the U.S. had secured 1.01 billion doses from six different companies up to November 20 which represents the highest quantity of any government apart from India which has made agreements for 1.6 billion. Pfizer/BioNTech and Moderna both account for 100 million U.S. doses each while the U.S. is also set for 500 million doses of the vaccine being developed by the University of Oxford and AstraZeneca.

https://www.statista.com/chart/23660/umber-of-doses-of-covid-19-vaccines-secured-by-the-us/

Content

This chart shows the number of doses of Covid-19 vaccines secured by the U.S. as of November 20, 2020.

Acknowledgements

Niall McCarthy, Data Journalist.

https://www.statista.com/chart/23660/umber-of-doses-of-covid-19-vaccines-secured-by-the-us/

Inspiration

Covid-19 Pandemic.

The Vaccines Market size was valued at USD 43.2 Billion in 2023 and is projected to reach USD 90.7 Billion by 2032, exhibiting a CAGR of 6.4 % during the forecast period. Recent developments include: January 2023: Bharat Biotech launched an indigenously made nasal COVID-19 vaccine, iNCOVAC, for people older than 18 years., August 2022: GSK acquired Affinivax, Inc., a clinical-stage biopharmaceutical company, predominantly developing novel next generation pneumococcal vaccine. Through this acquisition, the company aims to strengthen its product portfolio., August 2022: Takeda Pharmaceutical Company Limited received the Indonesia National Agency for Drug and Food Control approval for its dengue tetravalent vaccine, QDenga for individuals six years to 45 years of age., July 2022: Bavarian Nordic, a Danish biotechnology company, received EU approval for Imvanex for protection against monkeypox disease., September 2021: The Serum Institute of India Pvt planned to launch at least one vaccine every quarter, beginning with Covishield, which is licensed from AstraZeneca., September 2020: The Serum Institute of India collaborated with Gavi and the Bill & Melinda Gates Foundation to accelerate the manufacture and delivery of up to an additional 100 million doses of safe and effective COVID-19 vaccines for Low and Middle-Income Countries (LMICs) as part of the Gavi COVAX AMC, which is a mechanism within the COVAX Facility.. Key drivers for this market are: Strong Supply Backed Up by Robust R&D to Fuel Market Growth. Potential restraints include: High Costs Associated with Vaccine Dose to Hinder Market Growth. Notable trends are: Growing Supply of Products by UNICEF, WHO, and PAHO to Aid Immunization Process.

Association of educational level and social-economic status with reluctance towards coronavirus disease vaccination and motivations for participation in vaccination among the general population of Shiraz.

About Dataset: WHO COVID-19 Global Data

This dataset provides comprehensive information on the global COVID-19 pandemic as reported to the World Health Organization (WHO). The dataset is available in comma-separated values (CSV) format and includes the following fields:

Daily cases and deaths by date reported to WHO: WHO-COVID-19-global-data.csv

• Date_reported (Date): The date of reporting to WHO.
• Country_code (String): The ISO Alpha-2 country code.
• Country (String): The name of the country, territory, or area.
• WHO_region (String): The WHO regional office to which the country belongs. WHO Member States are grouped into six WHO regions, including AFRO (Regional Office for Africa), AMRO (Regional Office for the Americas), SEARO (Regional Office for South-East Asia), EURO (Regional Office for Europe), EMRO (Regional Office for the Eastern Mediterranean), and WPRO (Regional Office for the Western Pacific).
• New_cases (Integer): The number of new confirmed cases reported on a given day. This is calculated by subtracting the previous cumulative case count from the current cumulative case count.
• Cumulative_cases (Integer): The total cumulative confirmed cases reported to WHO up to the specified date.
• New_deaths (Integer): The number of new confirmed deaths reported on a given day. Similar to new cases, this is calculated by subtracting the previous cumulative death count from the current cumulative death count.- Cumulative_deaths (Integer): The total cumulative confirmed deaths reported to WHO up to the specified date.

In addition to the COVID-19 case and death data, this dataset also includes valuable information related to COVID-19 vaccinations. The vaccination data consists of the following fields:

Vaccination Data Fields: vaccination-data.csv

• COUNTRY (String): Country, territory, or area.
• ISO3 (String): ISO Alpha-3 country code.
• WHO_REGION (String): The WHO regional office to which the country belongs.
• DATA_SOURCE (String): Indicates the data source, which can be either "REPORTING" (Data reported by Member States or sourced from official reports) or "OWID" (Data sourced from Our World in Data COVID-19 Vaccinations).
• DATE_UPDATED (Date): Date of the last update.
• TOTAL_VACCINATIONS (Integer): Cumulative total vaccine doses administered.
• PERSONS_VACCINATED_1PLUS_DOSE (Decimal): Cumulative number of persons vaccinated with at least one dose.
• TOTAL_VACCINATIONS_PER100 (Integer): Cumulative total vaccine doses administered per 100 population.
• PERSONS_VACCINATED_1PLUS_DOSE_PER100 (Decimal): Cumulative persons vaccinated with at least one dose per 100 population.
• PERSONS_LAST_DOSE (Integer): Cumulative number of persons vaccinated with a complete primary series.
• PERSONS_LAST_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with a complete primary series per 100 population.
• VACCINES_USED (String): Combined short name of the vaccine in the format "Company - Product name."
• FIRST_VACCINE_DATE (Date): Date of the first vaccinations, equivalent to the start/launch date of the first vaccine administered in a country.
• NUMBER_VACCINES_TYPES_USED (Integer): Number of vaccine types used per country, territory, or area.
• PERSONS_BOOSTER_ADD_DOSE (Integer): Cumulative number of persons vaccinated with at least one booster or additional dose.
• PERSONS_BOOSTER_ADD_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with at least one booster or additional dose per 100 population.

In addition to the vaccination data, a separate dataset containing vaccination metadata is available, including information about vaccine names, product names, company names, authorization dates, start and end dates of vaccine rollout, and more.

Vaccination metadata Fields: vaccination-metadata.csv

• ISO3 (String): ISO Alpha-3 country code
• VACCINE_NAME (String): Combined short name of vaccine: "Company - Product name" (see below)
• PRODUCT_NAME (String): Name or label of vaccine product, or type of vaccine (if unnamed).
• COMPANY_NAME (String): Marketing authorization holder of vaccine product.
• FIRST_VACCINE_DATE (Date): Date of first vaccinations. Equivalent to start/launch date of the first vaccine administered in a country.
• AUTHORIZATION_DATE (Date): Date vaccine product was authorized for use in the country, territory, area.
• START_DATE (Date): Start/launch date of vaccination with vaccine type (excludes vaccinations during clinical trials).
• END_DATE (Date): End date of vaccine rollout
• COMMENT (String): Comments related to vaccine rollout
• DATA_SOURCE (String): Indicates data source - REPORTING: Data reported by Member States, or sourced from official re...

SB: AK: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data was reported at 14.500 % in 28 Mar 2022. This records a decrease from the previous number of 23.100 % for 21 Mar 2022. SB: AK: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data is updated weekly, averaging 18.400 % from Feb 2021 (Median) to 28 Mar 2022, with 19 observations. The data reached an all-time high of 26.000 % in 15 Feb 2021 and a record low of 12.900 % in 31 May 2021. SB: AK: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S: Small Business Pulse Survey: by State: West Region: Weekly, Beg Monday (Discontinued).

Oral COVID-19 Vaccines Market Outlook

According to our latest research, the global oral COVID-19 vaccines market size reached USD 1.92 billion in 2024, reflecting a dynamic growth trajectory as the world continues to seek innovative vaccination strategies. The market is projected to expand at a robust CAGR of 16.1% from 2025 to 2033, with the forecasted market size expected to reach USD 8.51 billion by 2033. This substantial growth is driven by the increasing demand for needle-free vaccine delivery, enhanced patient compliance, and the need for scalable immunization solutions, especially in low-resource settings.

One of the primary growth factors for the oral COVID-19 vaccines market is the urgent global requirement for mass immunization with minimal logistical barriers. Traditional injectable vaccines, while highly effective, pose challenges related to cold chain requirements, trained healthcare personnel, and needle-associated hesitancy. Oral vaccines offer a compelling alternative by simplifying administration, reducing the risk of needle-stick injuries, and enabling rapid deployment during outbreaks. These advantages are particularly critical in rural and underserved areas, where access to healthcare infrastructure is limited. The ongoing innovation in vaccine formulation and delivery technologies is further propelling the adoption of oral vaccines, making them a cornerstone of future pandemic preparedness strategies.

Another significant driver is the evolving landscape of vaccine research and development, where pharmaceutical companies and research institutions are investing heavily in novel vaccine platforms. The flexibility of oral vaccines to be integrated with a variety of antigen types—including live attenuated, inactivated, and protein subunit vaccines—has expanded their application across different population cohorts. Additionally, oral vaccines have demonstrated promising results in preclinical and clinical trials, showing robust immunogenicity and favorable safety profiles. Strategic collaborations between biotech firms, global health organizations, and governments are accelerating the commercialization of these vaccines, ensuring that they reach markets swiftly and efficiently.

The increasing emphasis on patient-centric healthcare is also fueling the growth of the oral COVID-19 vaccines market. Oral administration is particularly advantageous for pediatric and geriatric populations, who often experience anxiety or discomfort with injections. The convenience of self-administration and reduced need for healthcare visits further enhance patient adherence, which is crucial for achieving widespread herd immunity. Moreover, the potential for oral vaccines to be distributed through pharmacies and online platforms broadens their accessibility, supporting national and international vaccination campaigns. As awareness about the benefits of oral vaccines continues to rise, market penetration is expected to deepen across all age groups.

Regionally, North America and Asia Pacific are leading the adoption of oral COVID-19 vaccines, driven by robust healthcare infrastructure, significant R&D investments, and proactive government initiatives. Europe is also witnessing steady growth, supported by strong regulatory frameworks and high public health awareness. Meanwhile, emerging economies in Latin America and the Middle East & Africa are increasingly recognizing the value of oral vaccines in overcoming logistical challenges. The regional landscape is characterized by diverse market dynamics, with local manufacturing capabilities, regulatory policies, and disease burden influencing the pace of adoption. As global partnerships and technology transfers intensify, the oral COVID-19 vaccines market is poised for sustained expansion across all major regions.

Vaccine Type Analysis

The oral COVID-19 vaccines market is segmented by vaccine type into live attenuated, inactivated, protein subunit, viral vector, and others. Each vaccine t

United States SB: MT: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data was reported at 15.000 % in 11 Apr 2022. This records an increase from the previous number of 12.500 % for 04 Apr 2022. United States SB: MT: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data is updated weekly, averaging 13.600 % from Nov 2021 (Median) to 11 Apr 2022, with 15 observations. The data reached an all-time high of 17.400 % in 28 Mar 2022 and a record low of 8.100 % in 15 Nov 2021. United States SB: MT: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S053: Small Business Pulse Survey: by State: West Region: Weekly, Beg Monday (Discontinued).

SB: MD: COVID Test/Vaccine: Proof of COVID Vaccination: Yes data was reported at 10.400 % in 11 Apr 2022. This records a decrease from the previous number of 11.000 % for 04 Apr 2022. SB: MD: COVID Test/Vaccine: Proof of COVID Vaccination: Yes data is updated weekly, averaging 19.500 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 19.500 % in 10 Jan 2022 and a record low of 8.500 % in 28 Mar 2022. SB: MD: COVID Test/Vaccine: Proof of COVID Vaccination: Yes data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S: Small Business Pulse Survey: by State: South Region: Weekly, Beg Monday (Discontinued).

Association of age and gender with reluctancy towards coronavirus disease vaccination and the motivation to participate in vaccination among the general population of Shiraz.